Conjugated linoleic acid is related to bone mineral density but does not affect parathyroid hormone in men
Conjugated linoleic acid is related to bone mineral density but does not affect parathyroid hormone in men
复制标题
DOI：
10.1016/j.nutres.2012.08.006
复制
发表时间：
2012-12-01
影响因子：
4.5
通讯作者：
Weiler, Hope A.
中科院分区：
文献类型：
--
作者：
DeGuire, Jason R.;Makarem, Nour;Weiler, Hope A.
共轭亚油酸（CLA）的地位，骨，身体组成，和共轭亚油酸对促钙激素的影响之间的关系尚不清楚。一项横断面研究旨在研究红细胞膜（RBC）中c9，t11 CLA状态与身体成分之间的关系。这之前的剂量反应试验调查，如果c9，t11 CLA影响甲状旁腺激素（PTH）。假设（1）RBC中较高的c9，t11 CLA状态将与较低的脂肪和较高的骨量相关，（2）补充c9，t11 CLA后PTH将降低30%。54名男性（年龄，19-53岁）被纳入横断面分析，其中31人在剂量反应试验中进行研究，并随机分为3组：安慰剂组（n = 10），1.5 g/d组（n = 11），或3.0 g/d组（n = 10）的c9，t11共轭亚油酸16周。RBC c9，t11 CLA状态高于中位数的男性全身骨密度（BMD）较高（1.359 +/- 0.024 vs 1.287 +/- 0.023 g/cm（2）; P = .04）和全身瘦体重（WBL）百分比（78.8% +/- 0.9% vs 75.3% +/- 1.0%; P = .01），而体重指数（24.8 +/- 0.5 kg/m2 vs 27.3 +/- 0.9 kg/m2; P = .01）和全身脂肪质量百分比（17.3% +/- 0.9% vs 21.3% +/- 1.1%; P = .007）较低。在回归分析中，RBC c9，t11 CLA状态占全身BMD变化的显著比例（r（2）= 0.10）（P = 0.03）。任何骨或骨代谢生物标志物（包括PTH）之间均无时间或治疗差异。这些发现表明RBC c9，t11 CLA状态，反映长期（类似于4个月）饮食CLA摄入量，与BMD呈正相关。然而，c9，t11 CLA补充剂似乎不会影响健康男性的PTH。(C)2012 Elsevier Inc. All rights reserved.
The relationships between conjugated linoleic acid (CLA) status, bone, body composition, and the effect of CLA on calciotropic hormones are unclear. A cross-sectional study was designed to examine the association between c9, t11 CLA status in erythrocyte membranes (RBC) and body composition. This preceded a dose-response trial investigating if c9, t11 CLA affected parathyroid hormone (PTH). It was hypothesized that (1) higher c9, t11 CLA status in RBC will be associated with a lower fat and higher bone mass and that (2) PTH will be reduced by 30% after supplementation of c9, t11 CLA. Fifty-four men (age, 19-53 years) were included in the cross-sectional analysis, of which 31 were studied in the dose-response trial and randomized to 1 of 3 groups: placebo (n = 10), 1.5 g/d (n = 11), or 3.0 g/d (n = 10) of c9, t11 CLA for 16 weeks. Men with RBC c9, t11 CLA status above the median had higher whole body bone mineral density (BMD) (1.359 +/- 0.024 vs 1.287 +/- 0.023 g/cm(2); P = .04) and whole body lean mass (WBL) percentage (78.8% +/- 0.9% vs 75.3% +/- 1.0%; P = .01), whereas body mass index (24.8 +/- 0.5 kg/m(2) vs 27.3 +/- 0.9 kg/m(2); P = .01) and whole body fat mass percentage (17.3% +/- 0.9% vs 21.3% +/- 1.1%; P = .007) were lower. In regression analysis, RBC c9, t11 CLA status accounted for a significant proportion (r(2) = 0.10) of the variation in whole body BMD (P = .03). There were no time or treatment differences among any bone or biomarkers of bone metabolism including PTH. These findings indicate that RBC c9, t11 CLA status, a reflection of long-term (similar to 4 months) dietary CLA intake, positively relates to BMD. However, c9, t11 CLA supplementation does not appear to affect PTH in healthy men. (C) 2012 Elsevier Inc. All rights reserved.